• We recommend against the use of PI monotherapy as initial therapy for treatment-naïve patients. 
  • We suggest the use of darunavir/r-based dual ART regimen with raltegravir in treatment-naïve patients with CD4 count >200 cells/µL and viral load <100,000 copies/mL where there is need to avoid abacavir and tenofovir.
  • We recommend against the use of PI-based dual ART with a single NNRTI, NRTI or CCR5 receptor antagonist for treatment-naïve patients.